Therapeutics
Developing Next Generation Therapeutics for Healthy Life
Pipeline
Oncology/Immuno-Oncology
-
Product(Partners)TargetIndicationRegionDiscoveryPreclinicalINDPH1PH2PH3BLA Filing
-
view more
Porustobart HBM4003
CTLA-4
Melanoma, HCC*, RCC* & Other Advanced Solid Tumors
Melanoma, HCC*, NEC/NET* & Other Advanced Solid Tumors
NSCLC* & Other Advanced Solid Tumors
Global
Global
Global
-
view more
HBM7008
B7H4x4-1BB
Solid Tumors
Ex-U.S. 1
-
HBM7022
CLDN18.2xCD3
Solid Tumors
Global License to AstraZeneca
-
HBM1022
CCR8
Solid Tumors
Global
-
view more
HBM1020
B7H7
Solid Tumors
Global
-
HBM1007
CD73
Solid Tumors
Global
-
HBM9033
MSLN ADC
Solid Tumors
Global
-
HBM9027
PD-L1xCD40
Solid Tumors
Global
-
HBM1047
CD200R1
Solid Tumors
Global
-
HBM7004
B7H4×CD3
Solid Tumors
Global
-
HBM9014
LIFR
Solid Tumors
Global
Immunology
-
Product(Partners)TargetIndicationRegionDiscoveryPreclinicalINDPH1PH2PH3BLA Filing
-
view more
Batoclimab HBM9161(HanAll)
FcRn
MG*
TED*
Greater China License to CSPC
Greater China License to CSPC
-
HBM9378
TSLP
Asthma
Global
-
HBM9022(AbbVie; Utrecht University; Erasmus MC)
SARS-COV-2
COVID-19
Global License to AbbVie
-
HBM
-
Partner
-
Registrational Clinical Trial
-
Monotherapy
-
PD1 / Chemo
-
Breakthrough Therapy Designation
* HCC = Hepatocellular Carcinoma
* RCC = Renal Cell Carcinoma
* NEC = Neuroendocrine Carcinoma
* NET = Neuroendocrine Tumour
* NSCLC = Non-Small Cell Lung Cancer
* MG = Myasthenia Gravis
* TED = Thyroid Eye Disease
* The U.S. rights of HBM7008 is out-licensed to Cullinan Oncology in February 2023
Publications
-
A Phase I Study of HBM4003, an anti-CTLA-4 Heavy Chain Only Monoclonal Antibody, in Combination with Toripalimab in Advanced Melanoma
-
Innovative B7H4 x CD3 & B7H4 x 4-1BB Bispecificsfor Solid Tumor Therapies
-
An anti-CTLA-4 heavy chain-only antibody with enhanced T reg depletion shows excellent preclinical efficacy and safety profile
-
TNF-α inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China
-
Therapeutic Response and Possible Biomarkers in Acute Attacks of Neuromyelitis Optica Spectrum Disorders: A Prospective Observational Study
-
Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers
-
SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model
-
A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies
-
Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes
-
A human monoclonal antibody blocking SARS-CoV-2 infection
-
Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein
-
Cell Engager Summit Exclusive Speaker Interview
-
Preclinical evaluation of HBM7022, an HBICE™ 2+1 CLDN18.2 x CD3 bispecific antibody, for gastric cancer
-
Development of fully human T-cell engaging bispecific antibodies targeting B7H4
-
Discovery of potent and functional human antibodies against a new B7-family member, B7H7, for cancer immunotherapy
-
HCAb Based Bispecific Immune Cell Engager (HBICE) Platform Enables Fast And Convenient Generation of the Next Generation Bispecific Antibodies with High Potency, Promising Safety Profiles and Excellent Developability
-
HBM1022, a Novel Anti-CCR8 Antibody, Depletes Tumor-infiltrating Regulatory T cells via Enhanced ADCC Activity, Mediates Potent Anti-Tumor Activity
-
Novel Monoclonal Antibodies (mAbs) Targeting Human CCR8 Provide Potential Candidates for Next Generation Cancer Immunotherapy
-
HBM1007 – A Highly Potent Anti-CD73 mAb Candidate For Mono And Combination IO Therapy
-
BCMA x CD3 Bispecific Antibody – A novel HBICE™-based Molecule with Efficient Tumor Killing and Minimal Cytokine Release
-
A New Generation of Fully Human anti-CTLA-4 Heavy Chain Only Antibody
Copyright © 2022 Harbour BioMed. All Rights Reserved 沪ICP备19015946号-1